Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EYA2 | O00167 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19615405 | 0.97 | TDP1 (0.32) | EYA2APPACETDP1TSHR | |
| SCHEMBL9051005 | 0.90 | TSHR (0.33) | EYA2APPACETDP1TSHR | |
| SCHEMBL4868996 | 0.87 | TSHR (0.35) | EYA2APPACETDP1TSHR | |
| SCHEMBL28428366 | 0.84 | TDP1 (0.33) | EYA2APPACETDP1TSHR | |
| SCHEMBL99172 | 0.78 | HDAC1 (0.37) | TDP1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL537217 | 0.75 | LMNA (0.48) | TSHRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL9280314 | 0.75 | GPR84 (0.48) | APPTDP1TSHR | |
| SCHEMBL11407728 | 0.75 | GPR84 (0.48) | APPTDP1TSHR | |
| SCHEMBL29195396 | 0.75 | GPR84 (0.48) | APPTDP1TSHR | |
| SCHEMBL28464460 | 0.75 | LMNA (0.48) | TSHRHDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300443-B1 | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-8263623-B2 | Triazol derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2012-09-11 | — | — | US | disclosed |
| WO-2010004517-A1 | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | PFIZER INC | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | TSLP, IL5, EPX | EYA2 3161/4885APP 3842/4885ACE 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.